Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Lupin Launches Generic Tricor Tablets In US

Pharma major Lupin Ltd., said its subsidiary Lupin Pharmaceuticals Inc. had launched its Fenofibrate tablets in 48 mg and 145 mg strengths in the US, for which it had received final approval from the US FDA.

Lupin's Fenofibrate tablets are the AB rated generic equivalent of Abbott's Tricor tablets and are indicated for primary hypercholesterolemia or mixed dyslipidemia and severe hypertriglyceridemia.

Abbott's Tricor tables, 48 mg and 145 mg, had sales of $1.26 billion as per IMS Health, June 2012.

Commenting on the approval, Lupin Pharmaceuticals CEO and Group President Vinita Gupta said, "We are very happy to bring this product to market in the US. Patients can be assured that they are receiving the same high quality product they have been accustomed to a a more affordable price."

At the BSE, Lupin shares are currently trading at Rs.565.50, up 0.60 percent from the previous close.

Click here to receive FREE breaking news email alerts for Lupin Ltd. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.